EGFR and colorectal carcinoma: Clinical trials (phase 1/2) of this therapeutic approach in CRC are currently underway with the drug Hu5F9-G4 as a single agent in combination with cetuximab (CET) (anti-EGFR IgG1 monoclonal Ab, used in disseminated CRC) [175].